📄 LIMINATUS PHARMA, INC.

📄 LIMINATUS PHARMA, INC. Liminatus Pharma, Inc. is a pre-clinical stage life sciences and pre-revenue company developing a next generation CD47 checkpoint inhibitor under a license agreement. The company holds an exclusive license to develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, along with companion diagnostics. It completed a business combination with Iris Acquisition Corp on April 30,2025. Key risk: Liminatus cannot assure you that it will ever develop, obtain regulatory approval of, commercialize, or generate significant revenue from any product candidate. Proceeds: We will not receive any of the proceeds from the sale of shares by the Selling Securityholders., We may receive up to approximately $79,350,000 from the exercise of outstanding Public Warrants and approximately $9,608,900 from the exercise of outstanding Private Warrants, assuming cash exercise in full., Net proceeds from warrant exercises, if any, will be used for

Liminatus Pharma, Inc. is a pre-clinical stage life sciences and pre-revenue company developing a next generation CD47 checkpoint inhibitor under a license agreement. The company holds an exclusive license to develop and commercialize products for the CD47 immune checkpoint inhibitor to treat solid cancers, along with companion diagnostics. It completed a business combination with Iris Acquisition Corp on April 30,2025.